Cargando…

Identifying Patients for Self-Administration of Omalizumab

Omalizumab, a recombinant anti-immunoglobulin E (IgE) monoclonal antibody, is indicated for moderate to severe allergic asthma, chronic spontaneous urticaria, and nasal polyps, and is approved for self-administration. However, specific guidance on identifying candidates with characteristics suitable...

Descripción completa

Detalles Bibliográficos
Autores principales:	Murphy, Kevin R., Winders, Tonya, Smith, Brandy, Millette, Lauren, Chipps, Bradley E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9859916/ https://www.ncbi.nlm.nih.gov/pubmed/36173511 http://dx.doi.org/10.1007/s12325-022-02308-w

Ejemplares similares

Correction to: Identifying Patients for Self-Administration of Omalizumab
por: Murphy, Kevin R., et al.
Publicado: (2022)

A Patient Charter for Chronic Obstructive Pulmonary Disease
por: Hurst, John R., et al.
Publicado: (2020)

Omalizumab and quality of life in nasal polyps: A post hoc analysis
por: Han, Joseph K., et al.
Publicado: (2022)

The impact of home treatment and self-administration of omalizumab on chronic urticaria
por: Wiuff, Anne Christine, et al.
Publicado: (2022)

Safety Evaluation of an Expedited Omalizumab Home Self-Administration Pathway
por: Hussain, Zobia, et al.
Publicado: (2021)

T cell activity in successful treatment of chronic urticaria with omalizumab
por: Sánchez-Machín, Inmaculada, et al.
Publicado: (2011)

Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics
por: Liu, Mark C., et al.
Publicado: (2021)

Omalizumab Has a Place in Therapy for Asthma Disease Management
por: Pesko, Lawrence J.
Publicado: (2009)

The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma
por: Chapman, Kenneth R., et al.
Publicado: (2019)

Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma
por: Casale, T. B., et al.
Publicado: (2017)

Global Quality Standard for Identification and Management of Severe Asthma
por: Haughney, John, et al.
Publicado: (2020)

271 Evaluation of Adverse Events Associated to Administration of Omalizumab
por: Gomez, R. Maximiliano, et al.
Publicado: (2012)

A Charter to Improve Patient Care in Severe Asthma
por: Menzies-Gow, Andrew, et al.
Publicado: (2018)

Quality Standard Position Statements for Health System Policy Changes in Diagnosis and Management of COPD: A Global Perspective
por: Bhutani, Mohit, et al.
Publicado: (2022)

Case Report: Self-Administration of Omalizumab in an Adolescent With Severe Asthma During SARS-CoV-2 Infection
por: Paladini, Erika, et al.
Publicado: (2021)

A Renewed Charter: Key Principles to Improve Patient Care in Severe Asthma
por: Menzies-Gow, Andrew, et al.
Publicado: (2022)

Omalizumab in Children
por: Licari, Amelia, et al.
Publicado: (2014)

Cytomegalic hepatitis in a patient receiving omalizumab
por: Gonçalves, R., et al.
Publicado: (2016)

Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange
por: Pennington, Luke F., et al.
Publicado: (2016)

Omalizumab—A Review
por: Godse, Kiran, et al.
Publicado: (2015)

Improving Care in Eosinophil-Associated Diseases: A Charter
por: Jackson, David J., et al.
Publicado: (2022)

4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
por: Snelder, S. M., et al.
Publicado: (2017)

Sex, Allergic Diseases and Omalizumab
por: Sirufo, Maria Maddalena, et al.
Publicado: (2022)

Severe asthma and the omalizumab option
por: Miller, Christopher WT, et al.
Publicado: (2008)

Omalizumab treatment in brittle asthma
por: Skiepko, Roman, et al.
Publicado: (2014)

The effect of COVID-19 on patients recieving omalizumab treatment
por: Sayaca, N., et al.
Publicado: (2023)

Omalizumab in patients with severe asthma and persistent sputum eosinophilia
por: Mukherjee, Manali, et al.
Publicado: (2019)

Metabolomics to identify omalizumab responders among children with severe asthma: A prospective study
por: Carraro, Silvia, et al.
Publicado: (2022)

Angiotensin II administration to COVID-19 patients is not advisable
por: Speth, Robert C.
Publicado: (2020)

Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma
por: Kotoulas, Serafeim Chrysovalantis, et al.
Publicado: (2022)

Omalizumab therapy in three patients with chronic autoimmune urticaria
por: Al-Ahmad, Mona
Publicado: (2010)

Effects of Omalizumab Treatment in Patients With Refractory Chronic Urticaria
por: Nam, Young-Hee, et al.
Publicado: (2012)

Omalizumab in allergic bronchopulmonary aspergillosis in patients with cystic fibrosis
por: Ashkenazi, Moshe, et al.
Publicado: (2018)

Benefits of omalizumab on anxiety and depression in patients with severe asthma
por: Uzer, Fatih, et al.
Publicado: (2018)

Appropriate selection for omalizumab treatment in patients with severe asthma?
por: Nygaard, Leo, et al.
Publicado: (2017)

Impact of Omalizumab on Anaphylaxis in Patients Treated for Chronic Urticaria
por: Song, Xiaoting, et al.
Publicado: (2023)

Omalizumab: Clinical Use for the Management of Asthma
por: Thomson, Neil C., et al.
Publicado: (2012)

Omalizumab for chronic urticaria in Latin America
por: Wilches, Paul, et al.
Publicado: (2016)

Urticaria and angioedema as possible reactions of omalizumab
por: Ozbagcivan, Ozlem, et al.
Publicado: (2018)

Treatment of estrogen-induced dermatitis with omalizumab
por: Ocana, Jesus A., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vsca8oavp4c77h5nhld5eap7l7